Mouse Monoclonal LDLR Antibody

Low-density lipoprotein receptor (LDLR) antibodies are tools used to study LDLR, a cell-surface protein critical for cholesterol homeostasis. LDLR mediates the uptake of LDL particles, regulating plasma cholesterol levels. Mutations in the LDLR gene cause familial hypercholesterolemia (FH), a disorder linked to premature atherosclerosis and cardiovascular disease. LDLR antibodies, typically monoclonal or polyclonal, enable researchers to detect, quantify, and visualize LDLR expression in tissues or cultured cells via techniques like Western blot, immunohistochemistry, and flow cytometry. These antibodies often target specific LDLR domains, such as the ligand-binding or cytoplasmic regions, to assess receptor function, trafficking, or degradation. In diagnostics, LDLR antibodies help identify FH patients with reduced receptor activity. Additionally, they are used in drug development, particularly for therapies targeting PCSK9-LDLR interactions to enhance cholesterol clearance. Recent studies also explore LDLR antibodies in cancer research, as LDLR overexpression in some tumors may influence lipid metabolism and cell proliferation. Their versatility makes LDLR antibodies essential for both basic research and clinical applications in metabolic and cardiovascular diseases.